By: Dr. Sebastián Marincolo, Director of Strategic Content & Editorial, Weed.de
Germany’s partial cannabis legalisation was originally designed to undercut the black market. It was also designed to protect the country’s youth and shield consumers from unsafe products.
The original reform plan envisioned nationwide retail stores, but these were dropped quickly after EU Commission objections. In their place came the two-pillar model: Pillar 1 legalised home cultivation and cannabis social clubs (Anbauvereinigungen), while Pillar 2 set up regional five-year scientific pilot projects, allowing licensed retailers to sell cannabis products to adult participants.
Pillar 2 was deferred for separate legislation that has yet to materialise. Critics argued that without retail infrastructure, the black market would persist unchallenged.
But they were wrong. Surprisingly, even this incomplete reform is succeeding: the EKOCAN evaluation, the federally mandated assessment of the Konsumcannabisgesetz (KCanG), shows the legal market expanding, youth consumption stable, cannabis-related crime declining, and crucially, the black market beginning to shrink (EKOCAN, 2025).
But peer-reviewed research reveals an unintended consequence: medical cannabis patients now face higher rates of stigmatisation than recreational users. This paradox exposes why the reform remains incomplete, and why Pillar 2 is no longer optional.
A September 2025 study in the Journal of Cannabis Research found that 47.1% of medical-only cannabis users reported perceived stigmatisation, compared to significantly lower rates among recreational users (Rosenkranz et al., 2025).
The same pattern held for self-stigma: 41.9% of medical users experienced internalised shame about their cannabis use.
This finding defies intuition. These are patients using authorised medicine under physician supervision. Yet the study’s authors note that the public still perceives cannabis primarily as ‘an illegal drug and not a medicine,’ leading patients to feel ashamed of using ‘a drug’ rather than ‘a medicine’ for symptom relief.
A separate qualitative study in BMC Public Health confirms this dynamic: patients reported being dismissed by healthcare providers, facing workplace discrimination, and encountering police who could not distinguish between medical and recreational use (Borojevic & Söhner, 2025).
Dr. Sebastián Marincolo
The root cause is structural. Germany’s reform technically created three legal pathways: the medical system, home cultivation, and cannabis social clubs (cannabis associations).
In practice, however, only the medical route functions at scale. Home cultivation requires space, expertise, equipment, and upfront investment, barriers that exclude millions of Germans living in small apartments or rental housing.
Cannabis social clubs faced protracted licensing delays; although 337 have now received approval as of October 2025, with an average membership of 275 people, they serve approximately 92,000 members – just 2% of Germany’s estimated 4.5 million cannabis users (BCAv, 2025; International CBC, 2025; Bundesgesundheitsministerium, 2025).
This leaves the medical system as the only viable legal pathway for most adults, a system now absorbing demand it was never designed to meet.
Research suggests this includes a substantial population of self-medicators. The Canadian Cannabis Survey 2020 found that 76% of people who use cannabis for medical purposes do not have authorisation from a health care professional – they are self-medicating for conditions like chronic pain, anxiety, and sleep disorders (Health Canada, 2021).
Dr Sebastián Marincolo
This pattern of unauthorised therapeutic use is consistent across jurisdictions and reflects a widespread phenomenon of individuals seeking symptom relief outside formal medical channels.
Telemedicine platforms have helped lower access barriers for patients struggling to find knowledgeable prescribing physicians.
According to official BfArM data, Germany imported approximately 142 tonnes of medical cannabis in the first three quarters of 2025, on track to exceed 190 tonnes by year’s end, a nearly sixfold increase from 2023, when imports totalled 32.5 tonnes (BfArM, 2025).
Critics suspect the surge in prescriptions reflects widespread abuse by healthy adults.
The reality is mostly different, and more nuanced: lowered barriers have definitely helped cannabis-naïve patients with severe illnesses access treatment; thousands of self-medicators have finally obtained proper medical guidance; and yes, some non-medical users access the medical channel because the regulated recreational market they were promised years ago never materialised.
The consequence is stigma flowing in both directions: patients dismissed as recreational users seeking legal cover, and responsible adults forced to ‘perform illness’ to access a regulated product.
November 5, 2025 No Comments
October 31, 2025 No Comments
October 29, 2025 No Comments
Germany’s new government has framed the cannabis law as a problem rather than a success. On October 8, 2025, the Federal Cabinet approved sweeping restrictions on telemedicine prescriptions, including mandatory in-person consultations, quarterly in-person follow-ups, and a ban on mail-order delivery of cannabis flowers (Gleiss Lutz, 2025). On November 21, 2025, the Bundesrat largely endorsed this restrictive approach. The legislation now moves to the Bundestag, where a vote is expected in early 2026.
Yet the EKOCAN evaluation found a system working largely as intended: legal supply growing, black market shrinking, and criminal cannabis offenses declining significantly.
To be sure, some telemedicine platforms have not complied with German advertising laws in the past. But telemedicine platforms are not the disease. Restricting them or even prohibiting telemedicine services for cannabis flowers will not eliminate demand; it will simply redirect it back to the black market.
Pillar 2, regional pilot projects for regulated commercial sales, offers the best structural solution. By creating a separate, legitimate pathway for adult use, it would allow the medical system to focus on genuine therapeutic applications while destigmatising both groups.
Without Pillar 2, patients and non-medical users will continue to be treated as suspects. And telemedicine will continue to bear the blame for a systemic failure it did not create.
Cities like Berlin, Frankfurt, and Hannover have submitted applications for Pillar 2 pilot projects. The regulatory framework exists. The scientific monitoring infrastructure is in place, what we need now is political buy in.
For thousands of patients who already struggle to find knowledgeable physicians willing to prescribe cannabis, and who have finally found relief through telemedicine, restricting access would mean a return to suffering, stigma, or the black market. Germany’s patients deserve better than to be collateral damage in a political debate.
The post Germany’s Hidden Stigma Crisis: Why Pillar 2 is Still Sorely Needed appeared first on Business of Cannabis.
Continue reading...
Germany’s partial cannabis legalisation was originally designed to undercut the black market. It was also designed to protect the country’s youth and shield consumers from unsafe products.
The original reform plan envisioned nationwide retail stores, but these were dropped quickly after EU Commission objections. In their place came the two-pillar model: Pillar 1 legalised home cultivation and cannabis social clubs (Anbauvereinigungen), while Pillar 2 set up regional five-year scientific pilot projects, allowing licensed retailers to sell cannabis products to adult participants.
Pillar 2 was deferred for separate legislation that has yet to materialise. Critics argued that without retail infrastructure, the black market would persist unchallenged.
But they were wrong. Surprisingly, even this incomplete reform is succeeding: the EKOCAN evaluation, the federally mandated assessment of the Konsumcannabisgesetz (KCanG), shows the legal market expanding, youth consumption stable, cannabis-related crime declining, and crucially, the black market beginning to shrink (EKOCAN, 2025).
But peer-reviewed research reveals an unintended consequence: medical cannabis patients now face higher rates of stigmatisation than recreational users. This paradox exposes why the reform remains incomplete, and why Pillar 2 is no longer optional.
The Counterintuitive Finding
A September 2025 study in the Journal of Cannabis Research found that 47.1% of medical-only cannabis users reported perceived stigmatisation, compared to significantly lower rates among recreational users (Rosenkranz et al., 2025).
The same pattern held for self-stigma: 41.9% of medical users experienced internalised shame about their cannabis use.
This finding defies intuition. These are patients using authorised medicine under physician supervision. Yet the study’s authors note that the public still perceives cannabis primarily as ‘an illegal drug and not a medicine,’ leading patients to feel ashamed of using ‘a drug’ rather than ‘a medicine’ for symptom relief.
A separate qualitative study in BMC Public Health confirms this dynamic: patients reported being dismissed by healthcare providers, facing workplace discrimination, and encountering police who could not distinguish between medical and recreational use (Borojevic & Söhner, 2025).
Dr. Sebastián Marincolo
The Single-Door Problem: By the Numbers
The root cause is structural. Germany’s reform technically created three legal pathways: the medical system, home cultivation, and cannabis social clubs (cannabis associations).
In practice, however, only the medical route functions at scale. Home cultivation requires space, expertise, equipment, and upfront investment, barriers that exclude millions of Germans living in small apartments or rental housing.
Cannabis social clubs faced protracted licensing delays; although 337 have now received approval as of October 2025, with an average membership of 275 people, they serve approximately 92,000 members – just 2% of Germany’s estimated 4.5 million cannabis users (BCAv, 2025; International CBC, 2025; Bundesgesundheitsministerium, 2025).
This leaves the medical system as the only viable legal pathway for most adults, a system now absorbing demand it was never designed to meet.
Research suggests this includes a substantial population of self-medicators. The Canadian Cannabis Survey 2020 found that 76% of people who use cannabis for medical purposes do not have authorisation from a health care professional – they are self-medicating for conditions like chronic pain, anxiety, and sleep disorders (Health Canada, 2021).
Dr Sebastián Marincolo
This pattern of unauthorised therapeutic use is consistent across jurisdictions and reflects a widespread phenomenon of individuals seeking symptom relief outside formal medical channels.
Telemedicine platforms have helped lower access barriers for patients struggling to find knowledgeable prescribing physicians.
According to official BfArM data, Germany imported approximately 142 tonnes of medical cannabis in the first three quarters of 2025, on track to exceed 190 tonnes by year’s end, a nearly sixfold increase from 2023, when imports totalled 32.5 tonnes (BfArM, 2025).
Critics suspect the surge in prescriptions reflects widespread abuse by healthy adults.
The reality is mostly different, and more nuanced: lowered barriers have definitely helped cannabis-naïve patients with severe illnesses access treatment; thousands of self-medicators have finally obtained proper medical guidance; and yes, some non-medical users access the medical channel because the regulated recreational market they were promised years ago never materialised.
The consequence is stigma flowing in both directions: patients dismissed as recreational users seeking legal cover, and responsible adults forced to ‘perform illness’ to access a regulated product.
Why is No One Talking About Germany’s Oversupply Problem?
Read More »November 5, 2025 No Comments
How Cannabis Interacts with Pain, Sleep & Anxiety
Read More »October 31, 2025 No Comments
Drug War 2.0 Puts International Cannabis Reform at Risk
Read More »October 29, 2025 No Comments
Telemedicine as Scapegoat
Germany’s new government has framed the cannabis law as a problem rather than a success. On October 8, 2025, the Federal Cabinet approved sweeping restrictions on telemedicine prescriptions, including mandatory in-person consultations, quarterly in-person follow-ups, and a ban on mail-order delivery of cannabis flowers (Gleiss Lutz, 2025). On November 21, 2025, the Bundesrat largely endorsed this restrictive approach. The legislation now moves to the Bundestag, where a vote is expected in early 2026.
Yet the EKOCAN evaluation found a system working largely as intended: legal supply growing, black market shrinking, and criminal cannabis offenses declining significantly.
To be sure, some telemedicine platforms have not complied with German advertising laws in the past. But telemedicine platforms are not the disease. Restricting them or even prohibiting telemedicine services for cannabis flowers will not eliminate demand; it will simply redirect it back to the black market.
The Case for Pillar 2: Destigmatization Through Separation
Pillar 2, regional pilot projects for regulated commercial sales, offers the best structural solution. By creating a separate, legitimate pathway for adult use, it would allow the medical system to focus on genuine therapeutic applications while destigmatising both groups.
Without Pillar 2, patients and non-medical users will continue to be treated as suspects. And telemedicine will continue to bear the blame for a systemic failure it did not create.
The Decision Point
Cities like Berlin, Frankfurt, and Hannover have submitted applications for Pillar 2 pilot projects. The regulatory framework exists. The scientific monitoring infrastructure is in place, what we need now is political buy in.
For thousands of patients who already struggle to find knowledgeable physicians willing to prescribe cannabis, and who have finally found relief through telemedicine, restricting access would mean a return to suffering, stigma, or the black market. Germany’s patients deserve better than to be collateral damage in a political debate.
The post Germany’s Hidden Stigma Crisis: Why Pillar 2 is Still Sorely Needed appeared first on Business of Cannabis.
Continue reading...
